Close Menu

NEW YORK (360Dx) – Sygnis today reported a sharp increase in its third quarter and nine-month revenues.

For the three months ended Sept. 30, the Heidelberg, Germany-based firm said that revenues reached €2.4 million ($2.8 million), up 446 percent from the year-ago period. Sygnis did not disclose its Q3 2016 revenue figure.

For the nine months ended Sept. 30, the company reported revenues grew to €5.3 million, up from €976,000 from a year ago.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Kelvin Droegemeier, the director of the White House Office of Science and Technology Policy, is the new acting director of the US National Science Foundation.

An opinion piece at the Guardian discusses the state of SARS-CoV-2 testing in the UK.

Wired reports the University of California, Berkeley's Innovative Genomics Institute has transformed itself into a diagnostic lab to run SARS-CoV-2 tests.

In Nature this week: direct-capture Perturb-seq approach for combinatorial single-cell CRISPR screens, potential uses of genome-editing in breeding crops, and more.